相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Loretta J. Nastoupil et al.
LANCET HAEMATOLOGY (2019)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P. Sharman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew Lunning et al.
BLOOD (2019)
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
Tycel J. Phillips et al.
BLOOD (2018)
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Howard A. Burris et al.
LANCET ONCOLOGY (2018)
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Andrew D. Zelenetz et al.
LANCET ONCOLOGY (2017)
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
Sonali M. Smith et al.
LANCET HAEMATOLOGY (2017)
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
Paul M. Barr et al.
BLOOD (2016)
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Benjamin L. Lampson et al.
BLOOD (2016)
Long-term follow-up of the PI3Kb inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated analysis of TGR-1202 monotherapy and combined with ublituximab.
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials
Laurie H. Sehn et al.
BLOOD (2016)
Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202
Kamira Karen Maharaj et al.
BLOOD (2016)
Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma
Ian W. Flinn et al.
BLOOD (2016)
Idelalisib-associated Colitis Histologic Findings in 14 Patients
Anna-Sophie Weidner et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
Chan Yoon Cheah et al.
BLOOD (2015)
A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2015)
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E. Coutre et al.
LEUKEMIA & LYMPHOMA (2015)
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown et al.
BLOOD (2014)
The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms
Sara H. Hazem et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2014)
Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model
Tycho Baumann et al.
HAEMATOLOGICA (2014)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H. Quach et al.
LEUKEMIA (2010)
分享论文
